Ozone therapy in ethidium bromide-induced demyelination in rats: possible protective effect [abstract]

Auteurs

  • Mohga Samy

DOI :

https://doi.org/10.7203/jo3t.3.4.2019.15518

Mots-clés :

multiple sclerosis, ozone therapy

Résumé

BACKGROUND: Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system and it is characterized by excessive demyelination PURPOSE: The study aim to investigate the possible protective effect of ozone (O3) in ethidium bromide (EB) induced demyelination in rats either alone or in combination with corticosteroid in order to decreases the dose of steroid therapy. MATERIAL and METHODS: Rats were divided into 7 groups Group (1) normal control rats received saline. Group (2) sham-operated rats received saline. Group (3) sham operated rats received oxygen. Group (4) EB-treated rats received EB. Group (5) EB treated rats received oxygen. Group (6) EB treated rats received methyl prednisolone (MP) Group (7) EB treated rats received half the dose of MP concomitant with ozone. RESULTS: Significant improvement in the brain serotonin, dopamine, noradrenalin. A reduction of MDA,TNF-COX2 immune-reactivity was noticed in MP and oxygen groups . Furthermore, best amelioration was achieved by combining half the dose of methyl-prednisolone with ozone. CONCLUSION: We concluded that ozone has a protective effect on demyelination and can be used due to its protective effect in demyelinating diseases such as multiple sclerosis.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Téléchargements

Publiée

2019-12-19

Comment citer

Samy, M. (2019). Ozone therapy in ethidium bromide-induced demyelination in rats: possible protective effect [abstract]. Journal of Ozone Therapy, 3(4), 34. https://doi.org/10.7203/jo3t.3.4.2019.15518
Métriques
Vues/Téléchargements
  • Résumé
    393
  • PDF
    224

Numéro

Vol. 3 No 4 (2019)

Rubrique

Proceedings

Licence

Journal of Ozone Therapy applies the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC 4.0) license to works we publish.

Creative Commons License

Under this license, authors retain ownership of the copyright for their content, but allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. No permission is required from the authors or the publishers.
You may not use the material for commercial purposes.

Appropriate attribution can be provided by simply citing the original article, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Metrics